Kepler Capital Remains a Buy on Norsk Hydro Asa (0Q11)
In a report released on June 5, Martin Granviken from Kepler Capital maintained a Buy rating on Norsk Hydro Asa (0Q11 – Research Report), with a price target of NOK64.00. The company's shares closed last Friday at NOK54.42.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Granviken is ranked #7837 out of 9593 analysts.
In addition to Kepler Capital , Norsk Hydro Asa also received a Buy from RBC Capital's Marina Calero in a report issued on June 4. However, on the same day, Nordea Markets downgraded Norsk Hydro Asa (LSE: 0Q11) to a Sell.
The company has a one-year high of NOK76.14 and a one-year low of NOK49.56. Currently, Norsk Hydro Asa has an average volume of 30.74K.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Discover UK Penny Stocks To Watch In June 2025
The UK market has faced challenges recently, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns about global economic recovery. Despite these broader market difficulties, certain investment opportunities remain attractive. Penny stocks, while often considered a relic of past trading days, still offer potential for growth when they are backed by strong financials and solid fundamentals. In this article, we explore several penny stocks that stand out as promising candidates for investors seeking hidden value in the UK market. Name Share Price Market Cap Financial Health Rating Foresight Group Holdings (LSE:FSG) £4.035 £453.9M ★★★★★★ Warpaint London (AIM:W7L) £4.70 £379.7M ★★★★★★ Cairn Homes (LSE:CRN) £1.876 £1.17B ★★★★★☆ Ultimate Products (LSE:ULTP) £0.756 £63.63M ★★★★★☆ Van Elle Holdings (AIM:VANL) £0.385 £41.66M ★★★★★★ Polar Capital Holdings (AIM:POLR) £4.525 £436.27M ★★★★★★ LSL Property Services (LSE:LSL) £2.99 £308.82M ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.095 £174.69M ★★★★★★ Croma Security Solutions Group (AIM:CSSG) £0.86 £11.84M ★★★★★★ Braemar (LSE:BMS) £2.31 £72.24M ★★★★★★ Click here to see the full list of 407 stocks from our UK Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Afentra plc is an upstream oil and gas company focused on operations in Africa, with a market cap of £107.65 million. Operations: The company's revenue is derived from its Oil & Gas - Exploration & Production segment, totaling $180.86 million. Market Cap: £107.65M Afentra plc, an upstream oil and gas company, has shown notable financial improvements with revenues reaching US$180.86 million for the year ending December 2024, a substantial increase from the previous year's US$26.39 million. The company transitioned to profitability with a net income of US$52.35 million compared to a prior net loss. Afentra's strong cash position exceeds its total debt, and its interest payments are well covered by EBIT at 9.4 times coverage. Despite significant insider selling recently, Afentra trades at good value relative to peers and has not experienced meaningful shareholder dilution over the past year. Navigate through the intricacies of Afentra with our comprehensive balance sheet health report here. Gain insights into Afentra's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Avingtrans plc, with a market cap of £135.24 million, provides engineered components, systems, and services to the energy, medical, and infrastructure industries across various global regions including the UK, Europe, USA, Africa, Middle East, Americas, Caribbean, China and Asia Pacific. Operations: The company generates revenue through its Energy Advanced Engineering Systems segment, which accounts for £146.03 million, and its Medical and Industrial Imaging segment, contributing £4.41 million. Market Cap: £135.24M Avingtrans plc, with a market cap of £135.24 million, operates in the energy and medical sectors, generating significant revenue through its Energy Advanced Engineering Systems segment (£146.03 million). Despite a negative earnings growth of -33.8% over the past year, the company has achieved an average annual earnings growth of 14.7% over five years. Avingtrans maintains a satisfactory net debt to equity ratio of 4.5%, with short-term assets (£98M) exceeding both short-term (£57.6M) and long-term liabilities (£23.3M). Its interest payments are well covered by EBIT (5.7x), though profit margins have decreased to 2.7%. Unlock comprehensive insights into our analysis of Avingtrans stock in this financial health report. Understand Avingtrans' earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Helios Underwriting plc, along with its subsidiaries, offers limited liability investment opportunities for shareholders in the Lloyd's insurance market in the UK and has a market cap of £172.74 million. Operations: Helios Underwriting plc does not report specific revenue segments. Market Cap: £172.74M Helios Underwriting plc, with a market cap of £172.74 million, has shown robust earnings growth of 236.7% over the past year, surpassing its five-year average of 59.2%. Despite a decline in revenue to £36 million and net income to £18.58 million for 2024, the company maintains high-quality earnings and strong financial health with short-term assets (£900M) covering both short-term (£858.2M) and long-term liabilities (£22.9M). Recent strategic changes include a share buyback program worth up to £2 million and executive appointments aimed at reducing underwriting risk and operational costs for future stability. Take a closer look at Helios Underwriting's potential here in our financial health report. Gain insights into Helios Underwriting's historical outcomes by reviewing our past performance report. Dive into all 407 of the UK Penny Stocks we have identified here. Looking For Alternative Opportunities? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:AET AIM:AVG and AIM:HUW. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Discover UK Penny Stocks To Watch In June 2025
The UK market has faced challenges recently, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns about global economic recovery. Despite these broader market difficulties, certain investment opportunities remain attractive. Penny stocks, while often considered a relic of past trading days, still offer potential for growth when they are backed by strong financials and solid fundamentals. In this article, we explore several penny stocks that stand out as promising candidates for investors seeking hidden value in the UK market. Name Share Price Market Cap Financial Health Rating Foresight Group Holdings (LSE:FSG) £4.035 £453.9M ★★★★★★ Warpaint London (AIM:W7L) £4.70 £379.7M ★★★★★★ Cairn Homes (LSE:CRN) £1.876 £1.17B ★★★★★☆ Ultimate Products (LSE:ULTP) £0.756 £63.63M ★★★★★☆ Van Elle Holdings (AIM:VANL) £0.385 £41.66M ★★★★★★ Polar Capital Holdings (AIM:POLR) £4.525 £436.27M ★★★★★★ LSL Property Services (LSE:LSL) £2.99 £308.82M ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.095 £174.69M ★★★★★★ Croma Security Solutions Group (AIM:CSSG) £0.86 £11.84M ★★★★★★ Braemar (LSE:BMS) £2.31 £72.24M ★★★★★★ Click here to see the full list of 407 stocks from our UK Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Afentra plc is an upstream oil and gas company focused on operations in Africa, with a market cap of £107.65 million. Operations: The company's revenue is derived from its Oil & Gas - Exploration & Production segment, totaling $180.86 million. Market Cap: £107.65M Afentra plc, an upstream oil and gas company, has shown notable financial improvements with revenues reaching US$180.86 million for the year ending December 2024, a substantial increase from the previous year's US$26.39 million. The company transitioned to profitability with a net income of US$52.35 million compared to a prior net loss. Afentra's strong cash position exceeds its total debt, and its interest payments are well covered by EBIT at 9.4 times coverage. Despite significant insider selling recently, Afentra trades at good value relative to peers and has not experienced meaningful shareholder dilution over the past year. Navigate through the intricacies of Afentra with our comprehensive balance sheet health report here. Gain insights into Afentra's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Avingtrans plc, with a market cap of £135.24 million, provides engineered components, systems, and services to the energy, medical, and infrastructure industries across various global regions including the UK, Europe, USA, Africa, Middle East, Americas, Caribbean, China and Asia Pacific. Operations: The company generates revenue through its Energy Advanced Engineering Systems segment, which accounts for £146.03 million, and its Medical and Industrial Imaging segment, contributing £4.41 million. Market Cap: £135.24M Avingtrans plc, with a market cap of £135.24 million, operates in the energy and medical sectors, generating significant revenue through its Energy Advanced Engineering Systems segment (£146.03 million). Despite a negative earnings growth of -33.8% over the past year, the company has achieved an average annual earnings growth of 14.7% over five years. Avingtrans maintains a satisfactory net debt to equity ratio of 4.5%, with short-term assets (£98M) exceeding both short-term (£57.6M) and long-term liabilities (£23.3M). Its interest payments are well covered by EBIT (5.7x), though profit margins have decreased to 2.7%. Unlock comprehensive insights into our analysis of Avingtrans stock in this financial health report. Understand Avingtrans' earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Helios Underwriting plc, along with its subsidiaries, offers limited liability investment opportunities for shareholders in the Lloyd's insurance market in the UK and has a market cap of £172.74 million. Operations: Helios Underwriting plc does not report specific revenue segments. Market Cap: £172.74M Helios Underwriting plc, with a market cap of £172.74 million, has shown robust earnings growth of 236.7% over the past year, surpassing its five-year average of 59.2%. Despite a decline in revenue to £36 million and net income to £18.58 million for 2024, the company maintains high-quality earnings and strong financial health with short-term assets (£900M) covering both short-term (£858.2M) and long-term liabilities (£22.9M). Recent strategic changes include a share buyback program worth up to £2 million and executive appointments aimed at reducing underwriting risk and operational costs for future stability. Take a closer look at Helios Underwriting's potential here in our financial health report. Gain insights into Helios Underwriting's historical outcomes by reviewing our past performance report. Dive into all 407 of the UK Penny Stocks we have identified here. Looking For Alternative Opportunities? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:AET AIM:AVG and AIM:HUW. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
7 hours ago
- Yahoo
Citi sees Gilead clinical holds as only ‘minor setback'
Citi analyst Geoff Meacham keeps a Buy rating on Gilead (GILD) with a $125 price target after the company announced a clinical hold on its Phase 2 WONDERS trials evaluating the combination of GS-1720 and GS-4182 for once-weekly oral HIV treatment. The hold was initiated due to safety concerns, specifically decreases in CD4+ T-cell and absolute lymphocyte counts observed in a subset of participants receiving the combination therapy, the analyst tells investors in a research note. Citi says the setback impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously anticipated in 2029 or 2030. The hold does not affect Gilead's other ongoing HIV programs, including lenacapavir development for both treatment and prevention including the monthly oral combinations, as no similar lymphocyte or CD4 effects have been observed in these studies, Citi points out. As such, the firm sees the holds as a 'minor setback' and continues to believe that lenacapavir in pre-exposure prophylaxis and expansion of several differentiated lenacapavir combos should offset potential Biktarvy 2028 Inflation Reduction Act negotiations. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Disclaimer & DisclosureReport an Issue FDA placed clinical hold on Gilead HIV treatment trials of GS-1720 Gilead down 2% to $111.14 after FDA placed hold on some HIV trials Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
